News | Amgen
WEBAMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024. 09.09.2024. AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024.
Amgen Inc. (AMGN) Latest Stock News & Headlines - Yahoo Finance
WEBGet the latest Amgen Inc. (AMGN) stock news and headlines to help you in your trading and investing decisions.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST …
WEBMay 16, 2024 · FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER. Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor. IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 …
Amgen claims success for two immune drugs, but results …
WEB2 days ago · To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. ... Amgen shared the top-line results from two Phase 3 trials during an investor presentation Tuesday. In ...
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
WEBAug 4, 2022 · Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease. Tavneos Adds to Amgen 's Decades-Long Leadership in Inflammation and Nephrology.
AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE …
WEBTHOUSAND OAKS, Calif., Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m. PT on Tuesday, Sept. 24, 2024, to discuss new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA ® (inebilizumab-cdon) Phase 3 programs. Jay Bradner, executive vice …
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
WEBOct 31, 2023 · "With the completion of the Horizon acquisition, Amgen has added rare disease medicines that fit well with our broad innovative portfolio." Key results include: Total revenues increased 4% to $6.9 billion in comparison to the third quarter of 2022, resulting from a 5% increase in product sales.
Amgen quarterly profit rises 15%, obesity drug trials are on track
WEBFeb 6 (Reuters) - Amgen (AMGN.O) on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of...
Amgen's muscular disorder drug meets main goal in late-stage …
WEB2 days ago · Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment for a skin condition known as atopic dermatitis. The drug also met all ...
Amgen dives deeper into rare disease drugs with $27.8 bln …
WEBDec 12, 2022 · Amgen shares dipped less than 1% to close at $276.78. With the deal, Amgen gains two fast-growing drugs, the thyroid eye disease treatment Tepezza and gout treatment Krystexxa.
- Some results have been removed
Skip to content